Commercialization, • 9/19/25 Designing Trials with the End in Mind: Building Market Access into Rare Disease Clinical Development Previous Purpose-Driven Metrics: Running Gene Therapy Trials with KPIs That Matter Next What Matters to Payers: Conversations You Should Start During Phase 2 You Might Also Like Case Studies in Rare Disease Commercialization: Lessons Learned Rare Isn’t Small: Incorporating Operational Excellence into Global, Multisite Rare Disease Trials Reducing Patient Burden in Rare Disease Trials How to Accelerate the Adoption of Decentralized Trials for Rare Disease Indications What Matters to Payers: Conversations You Should Start During Phase 2
Commercialization, • 9/19/25 Designing Trials with the End in Mind: Building Market Access into Rare Disease Clinical Development Previous Purpose-Driven Metrics: Running Gene Therapy Trials with KPIs That Matter Next What Matters to Payers: Conversations You Should Start During Phase 2 You Might Also Like Case Studies in Rare Disease Commercialization: Lessons Learned Rare Isn’t Small: Incorporating Operational Excellence into Global, Multisite Rare Disease Trials Reducing Patient Burden in Rare Disease Trials How to Accelerate the Adoption of Decentralized Trials for Rare Disease Indications What Matters to Payers: Conversations You Should Start During Phase 2
